diaDexus is a privately held biotechnology company that is focused on the discovery, development and commercialization of novel, patent protected diagnostic products with high clinical value. The company's lead product, the PLAC Test, measures Lp-PLA2 (lipoprotein-associated phospholipase A2) a vascular-specific inflammatory enzyme implicated in the formation of rupture-prone plaque. It is plaque rupture and thrombosis, not stenosis, that cause the majority of cardiovascular events. The PLAC Test is the only blood test cleared by the FDA as an aid in assessing risk for coronary heart disease, and ischemic stroke associated with atherosclerosis.

Research Development Foundation is an American private company that operates as noncommercial research organizations.

Develops genetically engineered plants

Compugen is a drug and diagnostic discovery company providing novel product candidates addressing important unmet therapeutic and diagnostic needs to pharmaceutical, biotech and diagnostic companies under milestone and royalty bearing, or other revenue sharing agreements. Unlike traditional high throughput trial and error experimental based discovery, Compugen's discovery efforts consist of in silico (by computer) hypothesis-driven product candidate prediction and selection followed by in vitro and in vivo experimental validation. Compugen's unique in silico prediction and selection capabilities are based on a broad and continuously growing infrastructure of proprietary scientific understandings and predictive platforms, algorithms, machine learning systems and other computational biology tools. Industry collaborations may be entered into before product candidate discovery is undertaken pursuant to "discovery on demand" type arrangements, or with respect to existing product candidates, can be initiated prior to, or at the proof of concept stage, or after selected preclinical activities have been undertaken by Compugen. In 2002, Compugen established an affiliate, Evogene Ltd. (TASE: EVGN.TA) - to utilize certain of the Company's in silico predictive discovery capabilities in agricultural biotechnology.

Pantarhei Bioscience BV (PRB) is a limited liability company (Besloten Vennootschap) located in the Netherlands focussing on the development of innovative concepts for woman’s health and hormone-related cancer treatments. PRB has founded a subsidiary company – Pantarhei Oncology (PRO) – to develop treatments for Endocrine Cancer. PRB has developed a product pipeline based on its ability to identify novel medical uses of existing molecules, drugs, hormones, biologicals and combinations thereof in these areas of medicine. The main areas of expertise of PRB are reproductive hormone related treatments and diseases such as contraception and menopausal hormone therapy (MHT). The main areas of expertise of PRO are breast cancer, prostate cancer and ovarian cancer . PRB develops patent protected new treatment concepts up to proof-of-concept (PoC) in the human (phase II). Using existing molecules often provides first evidence of safety. The business model of the Pantarhei companies is based on creating intellectual property (IP) of new concepts ad inventions, in-house project management and outsourcing of all research and development activities. After successful PoC, data and IP are licensed out to a licensee or partner for completion of clinical development (phase III), regulatory approval and sales and marketing by a licensee/partner.

Peking University Third Hospital is a private company headquartered in Beijing, China, that operates as a clinic.

ICCAS was founded in 1956. ICCAS is a multi-disciplinary research institute dedicated to the basic research in broad fields of chemical sciences, and to the key developments of the innovative high technologies aiming to the imperative national needs and important strategic targets, as well as to the collaborative high-technology applications and transfers. ICCAS is one of China’s leading chemistry research institutions with high international reputation.

Anhui Provincial Hospital, a subsidiary of Province of Anhui, is a Chinese company located in Hefei. The firm provides health related services.

Massachusetts General Hospital was established to provide care to Boston's sick, regardless of socioeconomic status—an innovative idea in 1811. In the words of their founder, John Warren, MD, “When in distress, every man becomes their neighbor.” They subsequently became the first teaching hospital for Harvard University’s new medical school and have been redefining excellence in healthcare ever since. They have remained at the forefront of medicine by fostering a culture of collaboration, pushing the boundaries of medical research, educating the brightest medical minds and maintaining an unwavering commitment to the diverse community they were created to serve. They believe that because of diversity they excel, through inclusion they respect their community, and with a keen focus on equity they serve, heal, educate and innovate at the highest levels. Their first priority is the well-being of their patients—near and far. As a team they are able to maintain a singular focus on providing the highest quality, most compassionate care to each and every patient.

West China Second University Hospital is a Chinese private company located in Chengdu. The firm provides women and children healthcare services.

Qingdao Zhuoyun Haizhi Medical Technology Co., Ltd., established on 2020-03-12, Business scope includes general items:Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;Business Management Consulting;business management;market survey(Does not include foreign investigations);trade broker;Technology Import and Export;Import and export agency;Import and export;sales agent;Sales of Class II Medical Devices;Production of Class I Medical Devices;Sales of Class I Medical Devices;Retailing of protective equipment for healthcare workers;Wholesale of protective equipment for medical staff;Domestic trade agent;Health Consulting Services(Does not include medical services);Remote Health Management Services;Corporate Image Planning;Information Consulting Service(Not including licensing information consulting services);Engage in investment activities with own funds;Supply Chain Management Services.(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)licensed items:Class III medical device business;Production of Class III Medical Devices;Production of Class II Medical Devices;Internet Information Service for Medical Devices;Production of protective equipment for medical personnel(Class II medical device);Inspection and testing service;Internet hospital services relying on physical hospitals.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,The specific business items are subject to the approval documents or licenses of relevant departments)

Lifeline Biotechnologies, Inc., a medical technology company, develops diagnostic equipment for the prevention, early diagnosis, and quick recovery of ailments. The company offers First Warning System, a non-invasive, non-compressive, and non-radiogenic device used in assisting the early discovery of breast tissue abnormalities in women. It also provides Mastascope, a hand held endoscope designed to enter the breast nipple via one of its milk ducts, permitting the physician to visualize the interior aspects of the breast; and Ovascope, an endoscope to visualize the ovarian surface in the search for cancer. Lifeline Biotechnologies, Inc. was incorporated in 1981 and is based in Reno, Nevada with operations in Europe.

Peking University Shenzhen Hospital is a private company headquartered in Guangdong, China. The firm operates hospitals.

Todos Medical Ltd. is an in vitro diagnostics company. It is focused on the development of novel blood tests for the early detection of cancer and Alzheimer's disease, and the distribution of comprehensive solutions for COVID-19 screening. It is also involved in the activities of breast cancer test, such as TM-B1 and TM-B2. The company was founded by Rami Zigdon and Udi Zelig on April 22, 2010 and is headquartered in Tel Aviv, Israel.

Oncomatryx is a biopharmaceutical company focused on the tumor microenvironment. Oncomatryx has developed precision drugs and diagnostic devices that target the tumor stroma. Oncomatryx Antibody-Drug Conjugates (ADCs) and human-derived proteins target peritumoral fibroblasts, endothelial cells and extracellular matrix that promote tumor invasiveness, drug resistance and immunosuppression. Oncomatryx ADCs bear novel proprietary payloads and linker derivatives that render an optimal therapeutic index against pancreatic cancer in vivo. Oncomatryx OMTX705, an ADC which targets cancer-associated fibroblasts (CAFs), inhibits pancreatic tumor growth in patient-derived xenograft mice, both as single agent and in combination with chemotherapy.

FertileSafe solves problems in the field of assisted reproduction technology. Their products include Clair, Esther, Darya, Sarah, Helia, E. Vit, and E. Sep. They specialize in the fields of cryobiology and reproduction technology.

Specialist in the diagnosis and therapy of cancer diseases

Kitazato Corp. is a Japanese private company that develops research methods and technologies for medical manufacturers.